Development of segmental superficial actinic porokeratosis during immunosuppressive therapy for pemphigus vulgaris

Acta Dermato-Venereologica

Volumn 90, Issue 2, 2010, Pages 212-213

  Buhl, Timo ^a   Wienrich, B Gregor ^a   Sieblist, Claudia ^a   Schön, Michael P ^a   Seitz, Cornelia S ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACTINIC POROKERATOSIS; AGED; CASE REPORT; DISSEMINATED SUPERFICIAL ACTINIC POROKERATOSIS; DRUG PULSE THERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; PEMPHIGUS VULGARIS; PRIORITY JOURNAL;

AGED; BIOPSY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOSIS, ACTINIC; PEMPHIGUS; POROKERATOSIS; SKIN;

EID: 77950293729     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0800     Document Type: Letter

References (11)

1. Palleschi GM, Torchia D. Porokeratosis of Mibelli and superficial disseminated porokeratosis. J Cutan Pathol 2008; 35: 253-255.
2. Kanitakis J, Euvrard S, Faure M, Claudy A. Porokeratosis and immunosuppression. Eur J Dermatol 1998; 8: 459-465.
3. Gilead L, Guberman D, Zlotogorski A, Vardy DA, Klaus SN. Immunosuppression-induced porokeratosis of Mibelli: complete regression of lesions upon cessation of immunosuppressive therapy. J Eur Acad Derm Venereol 1995; 5: 170-172.
4. Tsambaos D, Spiliopoulos T. Disseminated superficial porokeratosis: complete remission subsequent to discontinuation of immunosuppression. J Am Acad Dermatol 1993; 28: 651-652.
5. Zhang ZH, Wang ZM, Crosby ME, Wang HF, Xiang LH, Luan J, et al. Gene expression profiling of porokeratosis. J Cutan Pathol 2008; 35: 1058-1062.
6. Happle R. A rule concerning the segmental manifestation of autosomal dominant skin disorders. Review of clinical examples providing evidence for dichotomous types of severity. Arch Dermatol 1997; 133: 1505-1509.
7. Happle R. Loss of heterozygosity in human skin. J Am Acad Dermatol 1999; 41: 143-164.
8. Happle R. Cancer proneness of linear porokeratosis may be explained by allelic loss. Dermatology 1997; 195: 20-25.
9. Curnow P, Foley P, Baker C. Multiple squamous cell carcinomas complicating linear porokeratosis. Australas J Dermatol 2003; 44: 136-139.
10. Freyschmidt-Paul P, Hoffmann R, König A, Happle R. Linear porokeratosis superimposed on disseminated superficial actinic porokeratosis: report of two cases exemplifying the concept of type 2 segmental manifestation of autosomal dominant skin disorders. J Am Acad Dermatol 1999; 41: 644-647.
11. Boente Mdel C, Lopez-Baro AM, Frontini Mdel V, Asial RA. Linear porokeratosis associated with disseminated superficial actinic porokeratosis: a new example of type II segmental involvement. Pediatr Dermatol 2003; 20: 514-518.